• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Coordinated antiviral immune response in a patient with myeloma and systemic adenovirus infection post-BCMA CAR T cells.

作者信息

Kocoglu Mehmet H, Luetkens Tim, Bork Jacqueline T, Baddley John, Omili Destiny, Gebru Etse, Mulatu Rediet, Yamoah Daniel, Iraguha Thierry, Fan Xiaoxuan, Lesho Patricia, Yousaf Mohammad, Baker Jillian M, Dietze Kenneth A, Hankey Kim G, Badros Ashraf, Yared Jean A, Rapoport Aaron P, Hardy Nancy M, Atanackovic Djordje

机构信息

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.

Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.

出版信息

Blood Adv. 2024 Nov 26;8(22):5880-5884. doi: 10.1182/bloodadvances.2024012762.

DOI:10.1182/bloodadvances.2024012762
PMID:39058975
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11612371/
Abstract
摘要

相似文献

1
Coordinated antiviral immune response in a patient with myeloma and systemic adenovirus infection post-BCMA CAR T cells.一名多发性骨髓瘤患者在接受靶向B细胞成熟抗原（BCMA）的嵌合抗原受体（CAR）T细胞治疗后发生系统性腺病毒感染时的协调抗病毒免疫反应
Blood Adv. 2024 Nov 26;8(22):5880-5884. doi: 10.1182/bloodadvances.2024012762.
2
BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma.靶向B细胞成熟抗原（BCMA）的嵌合抗原受体T细胞（CAR-T）疗法作为浆母细胞性骨髓瘤患者的挽救疗法
Hematology. 2025 Dec;30(1):2481555. doi: 10.1080/16078454.2025.2481555. Epub 2025 Mar 27.
3
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.抗 BCMA/GPRC5D 双特异性 CAR T 细胞治疗复发或难治性多发性骨髓瘤患者的单臂、单中心、1 期临床试验
Lancet Haematol. 2024 Oct;11(10):e751-e760. doi: 10.1016/S2352-3026(24)00176-5. Epub 2024 Jul 23.
4
Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.COVID-19 感染后复发/难治性多发性骨髓瘤患者抗 BCMA CAR T 治疗：1 例报告。
J Med Case Rep. 2021 Feb 19;15(1):90. doi: 10.1186/s13256-020-02598-0.
5
Myeloma cell-intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy.骨髓瘤细胞内在的膜联蛋白A1升高和T细胞功能障碍导致CAR-T治疗后BCMA阴性复发。
Mol Ther. 2025 Jul 2;33(7):3375-3391. doi: 10.1016/j.ymthe.2025.03.001. Epub 2025 Mar 8.
6
Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma.新型CS1嵌合抗原受体T细胞（CAR-T细胞）和双特异性CS1- BCMA嵌合抗原受体T细胞可有效靶向多发性骨髓瘤。
Biomedicines. 2021 Oct 9;9(10):1422. doi: 10.3390/biomedicines9101422.
7
[Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].[两例在鼠源BCMA CAR-T细胞治疗后进展的难治性多发性骨髓瘤患者的人源化BCMA CAR-T细胞挽救治疗]
Zhonghua Xue Ye Xue Za Zhi. 2021 Jun 14;42(6):502-507. doi: 10.3760/cma.j.issn.0253-2727.2021.06.010.
8
sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma.复发多发性骨髓瘤中可溶性BCMA血浆水平动态变化及抗BCMA嵌合抗原受体T细胞治疗
Curr Issues Mol Biol. 2022 Mar 24;44(4):1463-1471. doi: 10.3390/cimb44040098.
9
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma.抗 BCMA CAR-T 细胞治疗浆细胞异常：POEMS 综合征和多发性骨髓瘤病例报告。
J Hematol Oncol. 2018 Oct 22;11(1):128. doi: 10.1186/s13045-018-0672-7.
10
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.双特异性 BCMA/CD24 CAR-T 细胞控制多发性骨髓瘤生长。
Nat Commun. 2024 Jan 19;15(1):615. doi: 10.1038/s41467-024-44873-4.

本文引用的文献

1
Adenovirus infection in allogeneic hematopoietic cell transplantation.腺病毒感染在异基因造血细胞移植中。
Transpl Infect Dis. 2023 Nov;25 Suppl 1:e14173. doi: 10.1111/tid.14173. Epub 2023 Oct 17.
2
Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies.血液系统恶性肿瘤嵌合抗原受体（CAR）-T 细胞治疗后的感染。
Transpl Infect Dis. 2023 Nov;25 Suppl 1:e14157. doi: 10.1111/tid.14157. Epub 2023 Oct 3.
3
Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
1例大B细胞淋巴瘤患者接受靶向CD19嵌合抗原受体T细胞治疗后发生腺病毒诱导的出血性膀胱炎
Immunotherapy. 2023 Nov;15(16):1369-1374. doi: 10.2217/imt-2023-0111. Epub 2023 Sep 18.
4
Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells.一名骨髓瘤患者在接受靶向B细胞成熟抗原的嵌合抗原受体T细胞治疗后发生免疫介导的面神经麻痹。
Haematologica. 2024 Feb 1;109(2):682-688. doi: 10.3324/haematol.2023.283296.
5
Humanization and characterization of a murine monoclonal neutralizing antibody against human adenovirus 7.人源化和鉴定抗人腺病毒 7 的鼠源单克隆中和抗体。
Virology. 2023 Jun;583:36-44. doi: 10.1016/j.virol.2023.04.008. Epub 2023 Apr 22.
6
Adenoviral Penton and Hexon Proteins Are Equivalent Immunogenic Targets of Virus-Specific T Cells after Hematopoietic Stem Cell Transplantation in Children.腺病毒五邻体和六邻体蛋白是儿童造血干细胞移植后病毒特异性 T 细胞的等效免疫原性靶标。
Transplant Cell Ther. 2023 Jun;29(6):391.e1-391.e7. doi: 10.1016/j.jtct.2023.03.013. Epub 2023 Mar 18.
7
Adenovirus Infection and Transplantation.腺病毒感染与移植。
Transplantation. 2022 May 1;106(5):920-927. doi: 10.1097/TP.0000000000003988. Epub 2021 Nov 24.
8
A novel human monoclonal antibody potently neutralizes human adenovirus serotype 7 by primarily targeting the adenovirus hexon protein.一种新型人源单克隆抗体主要通过靶向腺病毒六邻体蛋白来有效中和人腺病毒 7 型。
Virology. 2020 Apr;543:20-26. doi: 10.1016/j.virol.2019.12.005. Epub 2019 Dec 12.
9
Adenovirus infection and disease in recipients of hematopoietic cell transplantation.造血干细胞移植受者的腺病毒感染和疾病。
Curr Opin Infect Dis. 2019 Dec;32(6):591-600. doi: 10.1097/QCO.0000000000000605.
10
Adenovirus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.实体器官移植受者腺病毒感染：美国移植感染病学会实践社区指南。
Clin Transplant. 2019 Sep;33(9):e13527. doi: 10.1111/ctr.13527. Epub 2019 Apr 1.